180 Life Sciences Corp Financials
This page shows 180 Life Sciences Corp (ATNF) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
FY2025 was a financing-led asset build, with cash drain shifting from operations to heavy reinvestment.
The striking number is not the$450.5M net loss but its mismatch with$26.1M operating cash outflow: reported earnings collapsed, yet cash use did not, which points to FY2025 being dominated by non-cash hits rather than a comparable jump in day-to-day spending. The real cash drain came from expansion, with$244.3M of capital spending pushing free cash flow to-$270.3M .
Between FY2024 and FY2025, total assets jumped from
The balance sheet looks stronger on paper than it does in near-term liquidity: equity rose from
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of 180 Life Sciences Corp's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
180 Life Sciences Corp has an operating margin of -3565.8%, meaning the company retains $-3566 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses.
180 Life Sciences Corp carries a low D/E ratio of 0.28, meaning only $0.28 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 96/100, indicating a strong balance sheet with room for future borrowing.
180 Life Sciences Corp's current ratio of 0.33 is below the typical benchmark, resulting in a score of 1/100. This tight liquidity could limit financial flexibility if cash inflows slow.
While 180 Life Sciences Corp generated -$26.1M in operating cash flow, capex of $244.3M consumed most of it, leaving -$270.3M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
180 Life Sciences Corp generates a -188.2% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -153.3% the prior year.
180 Life Sciences Corp passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, 180 Life Sciences Corp generates $0.06 in operating cash flow (-$26.1M OCF vs -$450.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
180 Life Sciences Corp generated $6.5M in revenue in fiscal year 2025.
180 Life Sciences Corp reported -$450.5M in net income in fiscal year 2025. This represents a decrease of 3077.2% from the prior year.
180 Life Sciences Corp earned $-54.32 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 90.2% from the prior year.
Cash & Balance Sheet
180 Life Sciences Corp generated -$270.3M in free cash flow in fiscal year 2025, representing cash available after capex.
180 Life Sciences Corp held $8.0M in cash against $0 in long-term debt as of fiscal year 2025.
180 Life Sciences Corp had 19M shares outstanding in fiscal year 2025. This represents an increase of 5884.2% from the prior year.
Margins & Returns
180 Life Sciences Corp's operating margin was -3565.8% in fiscal year 2025, reflecting core business profitability.
180 Life Sciences Corp's net profit margin was -6881.3% in fiscal year 2025, showing the share of revenue converted to profit.
180 Life Sciences Corp's ROE was -188.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 34.9 percentage points from the prior year.
Capital Allocation
180 Life Sciences Corp spent $46.3M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.
180 Life Sciences Corp invested $244.3M in capex in fiscal year 2025, funding long-term assets and infrastructure.
ATNF Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.9M | N/A | $4.1M | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | N/A | N/A | $182K-24.3% | $241K | N/A | $252K+111.7% | $119K |
| SG&A Expenses | $7.5M | N/A | $224.6M+15855.9% | $1.4M-28.4% | $2.0M | N/A | $596K-62.6% | $1.6M |
| Operating Income | -$4.6M | N/A | -$220.5M-12642.3% | -$1.7M+12.0% | -$2.0M | N/A | -$596K+67.7% | -$1.8M |
| Interest Expense | $1.0M | N/A | $320K+11872.6% | $3K+5.2% | $3K | N/A | $0-100.0% | $11K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$76.3M | N/A | -$216.7M-12453.1% | -$1.7M+27.1% | -$2.4M | N/A | -$837K-7202.3% | $12K |
| EPS (Diluted) | $-3.64 | N/A | $-16.80 | $-0.30+94.6% | $-5.54 | N/A | $-5.43-54400.0% | $0.01 |
ATNF Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $207.6M-32.2% | $306.3M-69.7% | $1.0B+9320.4% | $10.7M-8.0% | $11.7M-8.7% | $12.8M+21.9% | $10.5M+167.7% | $3.9M |
| Current Assets | $82.5M+508.1% | $13.6M-97.6% | $561.9M+18073.6% | $3.1M-23.2% | $4.0M-21.7% | $5.1M+319.6% | $1.2M-47.8% | $2.3M |
| Cash & Equivalents | $65.9M+722.0% | $8.0M-85.0% | $53.3M+2303.1% | $2.2M-39.7% | $3.7M-19.5% | $4.6M+2942.1% | $150K-86.9% | $1.1M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $375K | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $39.3M-41.3% | $66.9M-88.1% | $564.2M+10477.8% | $5.3M+35.2% | $3.9M+12.3% | $3.5M-47.9% | $6.7M+55.6% | $4.3M |
| Current Liabilities | $13.3M-67.4% | $40.9M-26.6% | $55.8M+946.0% | $5.3M+35.3% | $3.9M+12.5% | $3.5M-45.1% | $6.4M+59.0% | $4.0M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $168.3M-29.7% | $239.4M-46.2% | $445.1M+8173.1% | $5.4M-30.2% | $7.7M-16.7% | $9.3M+147.8% | $3.7M+993.3% | -$418K |
| Retained Earnings | -$668.3M-12.9% | -$592.0M-63.4% | -$362.4M-148.8% | -$145.6M-1.2% | -$143.9M-1.7% | -$141.5M-9.5% | -$129.2M-0.7% | -$128.4M |
ATNF Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$20.4M-167.9% | -$7.6M+53.6% | -$16.4M-1397.0% | -$1.1M-23.8% | -$887K-42.0% | -$625K-160.4% | -$240K-133.0% | $727K |
| Capital Expenditures | $16.8M+2014.4% | $795K | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | -$37.3M-342.1% | -$8.4M | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $71.8M-42.4% | $124.7M | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $5.5M+100.8% | -$667.0M-180.8% | $825.5M+235735.0% | -$350K-11577.3% | -$3K-100.1% | $5.0M+1148.9% | -$481K-81.5% | -$265K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | $30.1M+87.0% | $16.1M | N/A | N/A | N/A | N/A | N/A |
ATNF Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -162.1% | N/A | -5364.6% | N/A | N/A | N/A | N/A | N/A |
| Net Margin | -2667.5% | N/A | -5273.3% | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -45.3% | N/A | -48.7%-16.6pp | -32.1%-1.4pp | -30.7% | N/A | -22.4% | N/A |
| Return on Assets | -36.7% | N/A | -21.5%-5.3pp | -16.1%+4.2pp | -20.3% | N/A | -8.0%-8.3pp | 0.3% |
| Current Ratio | 6.19+5.9 | 0.33-9.7 | 10.07+9.5 | 0.58-0.4 | 1.02-0.4 | 1.47+1.3 | 0.19-0.4 | 0.58 |
| Debt-to-Equity | 0.23-0.0 | 0.28-1.0 | 1.27+0.3 | 0.99+0.5 | 0.51+0.1 | 0.38-1.4 | 1.80+12.2 | -10.36 |
| FCF Margin | -1303.4% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: The current ratio is below 1.0 (0.33), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is 180 Life Sciences Corp's annual revenue?
180 Life Sciences Corp (ATNF) reported $6.5M in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is 180 Life Sciences Corp profitable?
No, 180 Life Sciences Corp (ATNF) reported a net income of -$450.5M in fiscal year 2025, with a net profit margin of -6881.3%.
What is 180 Life Sciences Corp's operating margin?
180 Life Sciences Corp (ATNF) had an operating margin of -3565.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is 180 Life Sciences Corp's net profit margin?
180 Life Sciences Corp (ATNF) had a net profit margin of -6881.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is 180 Life Sciences Corp's return on equity (ROE)?
180 Life Sciences Corp (ATNF) has a return on equity of -188.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is 180 Life Sciences Corp's free cash flow?
180 Life Sciences Corp (ATNF) generated -$270.3M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is 180 Life Sciences Corp's operating cash flow?
180 Life Sciences Corp (ATNF) generated -$26.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are 180 Life Sciences Corp's total assets?
180 Life Sciences Corp (ATNF) had $306.3M in total assets as of fiscal year 2025, including both current and long-term assets.
What are 180 Life Sciences Corp's capital expenditures?
180 Life Sciences Corp (ATNF) invested $244.3M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is 180 Life Sciences Corp's current ratio?
180 Life Sciences Corp (ATNF) had a current ratio of 0.33 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is 180 Life Sciences Corp's debt-to-equity ratio?
180 Life Sciences Corp (ATNF) had a debt-to-equity ratio of 0.28 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is 180 Life Sciences Corp's return on assets (ROA)?
180 Life Sciences Corp (ATNF) had a return on assets of -147.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is 180 Life Sciences Corp's cash runway?
Based on fiscal year 2025 data, 180 Life Sciences Corp (ATNF) had $8.0M in cash against an annual operating cash burn of $26.1M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is 180 Life Sciences Corp's Piotroski F-Score?
180 Life Sciences Corp (ATNF) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are 180 Life Sciences Corp's earnings high quality?
180 Life Sciences Corp (ATNF) has an earnings quality ratio of 0.06x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is 180 Life Sciences Corp?
180 Life Sciences Corp (ATNF) scores 16 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.